Jove
Visualize
Contact Us

Related Experiment Videos

Bladder contracture following intravesical BCG immunotherapy

H B Grossman1

  • 1Department of Surgery, University of Michigan Medical Center, Ann Arbor.

Urology
|April 1, 1993
PubMed
Summary

Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy can cause bladder issues. This report details two rare cases of persistent small bladder capacity over a year after BCG treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New treatment approaches for superficial and invasive bladder cancer.

Urologic oncology·2011
Same author

Markers of bladder cancer State of the art.

Urologic oncology·2011
Same author

Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study.

Urologic oncology·2011
Same author

Bladder cancer markers in patient management: the current perspective.

World journal of urology·2007
Same author

High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk.

Carcinogenesis·2007
Same author

E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer.

Clinical genetics·2006
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Urology
  • Oncology
  • Immunotherapy

Background:

  • Intravesical Bacillus Calmette-Guérin (BCG) is a standard treatment for non-muscle-invasive bladder cancer.
  • BCG immunotherapy commonly causes irritative voiding symptoms.

Observation:

  • Two patients developed persistent small-capacity bladders.
  • These symptoms occurred more than one year after completing intravesical BCG therapy.

Findings:

  • Bladder contracture is a rare but significant complication of intravesical BCG.
  • Prolonged bladder dysfunction can occur following BCG treatment.

Implications:

  • Clinicians should be aware of the potential for delayed bladder contracture after BCG.
  • Further research may be needed to understand and mitigate long-term bladder complications from BCG immunotherapy.

Related Experiment Videos